Global and Japan Neurodegenerative Diseases Drug Market Size, Status and Forecast 2021-2027

Global and Japan Neurodegenerative Diseases Drug Market Size, Status and Forecast 2021-2027

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Diseases Drug Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Immunomodulator
1.2.3 Interferons
1.2.4 Decarboxylase Inhibitors
1.2.5 Dopamine Agonists
1.2.6 Others
1.3 Market by Application
1.3.1 Global Neurodegenerative Diseases Drug Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Multiple Sclerosis
1.3.3 Parkinson's Disease
1.3.4 Alzheimer's Disease
1.3.5 Spinal Muscular Atrophy (SMA)
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Neurodegenerative Diseases Drug Market Perspective (2016-2027)
2.2 Neurodegenerative Diseases Drug Growth Trends by Regions
2.2.1 Neurodegenerative Diseases Drug Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Neurodegenerative Diseases Drug Historic Market Share by Regions (2016-2021)
2.2.3 Neurodegenerative Diseases Drug Forecasted Market Size by Regions (2022-2027)
2.3 Neurodegenerative Diseases Drug Industry Dynamic
2.3.1 Neurodegenerative Diseases Drug Market Trends
2.3.2 Neurodegenerative Diseases Drug Market Drivers
2.3.3 Neurodegenerative Diseases Drug Market Challenges
2.3.4 Neurodegenerative Diseases Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Diseases Drug Players by Revenue
3.1.1 Global Top Neurodegenerative Diseases Drug Players by Revenue (2016-2021)
3.1.2 Global Neurodegenerative Diseases Drug Revenue Market Share by Players (2016-2021)
3.2 Global Neurodegenerative Diseases Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Neurodegenerative Diseases Drug Revenue
3.4 Global Neurodegenerative Diseases Drug Market Concentration Ratio
3.4.1 Global Neurodegenerative Diseases Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Diseases Drug Revenue in 2020
3.5 Neurodegenerative Diseases Drug Key Players Head office and Area Served
3.6 Key Players Neurodegenerative Diseases Drug Product Solution and Service
3.7 Date of Enter into Neurodegenerative Diseases Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurodegenerative Diseases Drug Breakdown Data by Type
4.1 Global Neurodegenerative Diseases Drug Historic Market Size by Type (2016-2021)
4.2 Global Neurodegenerative Diseases Drug Forecasted Market Size by Type (2022-2027)
5 Neurodegenerative Diseases Drug Breakdown Data by Application
5.1 Global Neurodegenerative Diseases Drug Historic Market Size by Application (2016-2021)
5.2 Global Neurodegenerative Diseases Drug Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Neurodegenerative Diseases Drug Market Size (2016-2027)
6.2 North America Neurodegenerative Diseases Drug Market Size by Type
6.2.1 North America Neurodegenerative Diseases Drug Market Size by Type (2016-2021)
6.2.2 North America Neurodegenerative Diseases Drug Market Size by Type (2022-2027)
6.2.3 North America Neurodegenerative Diseases Drug Market Size by Type (2016-2027)
6.3 North America Neurodegenerative Diseases Drug Market Size by Application
6.3.1 North America Neurodegenerative Diseases Drug Market Size by Application (2016-2021)
6.3.2 North America Neurodegenerative Diseases Drug Market Size by Application (2022-2027)
6.3.3 North America Neurodegenerative Diseases Drug Market Size by Application (2016-2027)
6.4 North America Neurodegenerative Diseases Drug Market Size by Country
6.4.1 North America Neurodegenerative Diseases Drug Market Size by Country (2016-2021)
6.4.2 North America Neurodegenerative Diseases Drug Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Neurodegenerative Diseases Drug Market Size (2016-2027)
7.2 Europe Neurodegenerative Diseases Drug Market Size by Type
7.2.1 Europe Neurodegenerative Diseases Drug Market Size by Type (2016-2021)
7.2.2 Europe Neurodegenerative Diseases Drug Market Size by Type (2022-2027)
7.2.3 Europe Neurodegenerative Diseases Drug Market Size by Type (2016-2027)
7.3 Europe Neurodegenerative Diseases Drug Market Size by Application
7.3.1 Europe Neurodegenerative Diseases Drug Market Size by Application (2016-2021)
7.3.2 Europe Neurodegenerative Diseases Drug Market Size by Application (2022-2027)
7.3.3 Europe Neurodegenerative Diseases Drug Market Size by Application (2016-2027)
7.4 Europe Neurodegenerative Diseases Drug Market Size by Country
7.4.1 Europe Neurodegenerative Diseases Drug Market Size by Country (2016-2021)
7.4.2 Europe Neurodegenerative Diseases Drug Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Diseases Drug Market Size (2016-2027)
8.2 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Type
8.2.1 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Type (2016-2027)
8.3 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Application
8.3.1 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Application (2016-2027)
8.4 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region
8.4.1 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Neurodegenerative Diseases Drug Market Size (2016-2027)
9.2 Latin America Neurodegenerative Diseases Drug Market Size by Type
9.2.1 Latin America Neurodegenerative Diseases Drug Market Size by Type (2016-2021)
9.2.2 Latin America Neurodegenerative Diseases Drug Market Size by Type (2022-2027)
9.2.3 Latin America Neurodegenerative Diseases Drug Market Size by Type (2016-2027)
9.3 Latin America Neurodegenerative Diseases Drug Market Size by Application
9.3.1 Latin America Neurodegenerative Diseases Drug Market Size by Application (2016-2021)
9.3.2 Latin America Neurodegenerative Diseases Drug Market Size by Application (2022-2027)
9.3.3 Latin America Neurodegenerative Diseases Drug Market Size by Application (2016-2027)
9.4 Latin America Neurodegenerative Diseases Drug Market Size by Country
9.4.1 Latin America Neurodegenerative Diseases Drug Market Size by Country (2016-2021)
9.4.2 Latin America Neurodegenerative Diseases Drug Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Diseases Drug Market Size (2016-2027)
10.2 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Type
10.2.1 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Type (2016-2027)
10.3 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Application
10.3.1 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Application (2016-2027)
10.4 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country
10.4.1 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Details
11.1.2 Biogen Business Overview
11.1.3 Biogen Neurodegenerative Diseases Drug Introduction
11.1.4 Biogen Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.1.5 Biogen Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Neurodegenerative Diseases Drug Introduction
11.2.4 Pfizer Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.2.5 Pfizer Recent Development
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Neurodegenerative Diseases Drug Introduction
11.3.4 Roche Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.3.5 Roche Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Neurodegenerative Diseases Drug Introduction
11.4.4 Novartis Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.4.5 Novartis Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Details
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Neurodegenerative Diseases Drug Introduction
11.5.4 Sanofi Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.5.5 Sanofi Recent Development
11.6 Teva Pharmaceuticals
11.6.1 Teva Pharmaceuticals Company Details
11.6.2 Teva Pharmaceuticals Business Overview
11.6.3 Teva Pharmaceuticals Neurodegenerative Diseases Drug Introduction
11.6.4 Teva Pharmaceuticals Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.6.5 Teva Pharmaceuticals Recent Development
11.7 Orion Pharma Ltd
11.7.1 Orion Pharma Ltd Company Details
11.7.2 Orion Pharma Ltd Business Overview
11.7.3 Orion Pharma Ltd Neurodegenerative Diseases Drug Introduction
11.7.4 Orion Pharma Ltd Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.7.5 Orion Pharma Ltd Recent Development
11.8 UCB S.A
11.8.1 UCB S.A Company Details
11.8.2 UCB S.A Business Overview
11.8.3 UCB S.A Neurodegenerative Diseases Drug Introduction
11.8.4 UCB S.A Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.8.5 UCB S.A Recent Development
11.9 ACADIA Pharmaceuticals Inc.
11.9.1 ACADIA Pharmaceuticals Inc. Company Details
11.9.2 ACADIA Pharmaceuticals Inc. Business Overview
11.9.3 ACADIA Pharmaceuticals Inc. Neurodegenerative Diseases Drug Introduction
11.9.4 ACADIA Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.9.5 ACADIA Pharmaceuticals Inc. Recent Development
11.10 Lundbeck Pharmaceuticals Italy S.p.A.
11.10.1 Lundbeck Pharmaceuticals Italy S.p.A. Company Details
11.10.2 Lundbeck Pharmaceuticals Italy S.p.A. Business Overview
11.10.3 Lundbeck Pharmaceuticals Italy S.p.A. Neurodegenerative Diseases Drug Introduction
11.10.4 Lundbeck Pharmaceuticals Italy S.p.A. Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.10.5 Lundbeck Pharmaceuticals Italy S.p.A. Recent Development
11.11 Mitsubishi Tanabe Pharma America
11.11.1 Mitsubishi Tanabe Pharma America Company Details
11.11.2 Mitsubishi Tanabe Pharma America Business Overview
11.11.3 Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Introduction
11.11.4 Mitsubishi Tanabe Pharma America Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.11.5 Mitsubishi Tanabe Pharma America Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Neurodegenerative Diseases Drug Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Immunomodulator
Table 3. Key Players of Interferons
Table 4. Key Players of Decarboxylase Inhibitors
Table 5. Key Players of Dopamine Agonists
Table 6. Key Players of Others
Table 7. Global Neurodegenerative Diseases Drug Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Neurodegenerative Diseases Drug Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Neurodegenerative Diseases Drug Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Neurodegenerative Diseases Drug Market Share by Regions (2016-2021)
Table 11. Global Neurodegenerative Diseases Drug Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Neurodegenerative Diseases Drug Market Share by Regions (2022-2027)
Table 13. Neurodegenerative Diseases Drug Market Trends
Table 14. Neurodegenerative Diseases Drug Market Drivers
Table 15. Neurodegenerative Diseases Drug Market Challenges
Table 16. Neurodegenerative Diseases Drug Market Restraints
Table 17. Global Neurodegenerative Diseases Drug Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Neurodegenerative Diseases Drug Market Share by Players (2016-2021)
Table 19. Global Top Neurodegenerative Diseases Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurodegenerative Diseases Drug as of 2020)
Table 20. Ranking of Global Top Neurodegenerative Diseases Drug Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Neurodegenerative Diseases Drug Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Neurodegenerative Diseases Drug Product Solution and Service
Table 24. Date of Enter into Neurodegenerative Diseases Drug Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Neurodegenerative Diseases Drug Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Neurodegenerative Diseases Drug Revenue Market Share by Type (2016-2021)
Table 28. Global Neurodegenerative Diseases Drug Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Neurodegenerative Diseases Drug Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Neurodegenerative Diseases Drug Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Neurodegenerative Diseases Drug Revenue Market Share by Application (2016-2021)
Table 32. Global Neurodegenerative Diseases Drug Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Neurodegenerative Diseases Drug Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Neurodegenerative Diseases Drug Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Neurodegenerative Diseases Drug Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Neurodegenerative Diseases Drug Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Neurodegenerative Diseases Drug Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Neurodegenerative Diseases Drug Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Neurodegenerative Diseases Drug Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Neurodegenerative Diseases Drug Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Neurodegenerative Diseases Drug Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Neurodegenerative Diseases Drug Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Neurodegenerative Diseases Drug Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Neurodegenerative Diseases Drug Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Neurodegenerative Diseases Drug Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Neurodegenerative Diseases Drug Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Neurodegenerative Diseases Drug Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Neurodegenerative Diseases Drug Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Neurodegenerative Diseases Drug Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Neurodegenerative Diseases Drug Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Neurodegenerative Diseases Drug Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Neurodegenerative Diseases Drug Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Neurodegenerative Diseases Drug Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Neurodegenerative Diseases Drug Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Neurodegenerative Diseases Drug Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Neurodegenerative Diseases Drug Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Neurodegenerative Diseases Drug Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Neurodegenerative Diseases Drug Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Neurodegenerative Diseases Drug Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country (2022-2027) & (US$ Million)
Table 64. Biogen Company Details
Table 65. Biogen Business Overview
Table 66. Biogen Neurodegenerative Diseases Drug Product
Table 67. Biogen Revenue in Neurodegenerative Diseases Drug Business (2016-2021) & (US$ Million)
Table 68. Biogen Recent Development
Table 69. Pfizer Company Details
Table 70. Pfizer Business Overview
Table 71. Pfizer Neurodegenerative Diseases Drug Product
Table 72. Pfizer Revenue in Neurodegenerative Diseases Drug Business (2016-2021) & (US$ Million)
Table 73. Pfizer Recent Development
Table 74. Roche Company Details
Table 75. Roche Business Overview
Table 76. Roche Neurodegenerative Diseases Drug Product
Table 77. Roche Revenue in Neurodegenerative Diseases Drug Business (2016-2021) & (US$ Million)
Table 78. Roche Recent Development
Table 79. Novartis Company Details
Table 80. Novartis Business Overview
Table 81. Novartis Neurodegenerative Diseases Drug Product
Table 82. Novartis Revenue in Neurodegenerative Diseases Drug Business (2016-2021) & (US$ Million)
Table 83. Novartis Recent Development
Table 84. Sanofi Company Details
Table 85. Sanofi Business Overview
Table 86. Sanofi Neurodegenerative Diseases Drug Product
Table 87. Sanofi Revenue in Neurodegenerative Diseases Drug Business (2016-2021) & (US$ Million)
Table 88. Sanofi Recent Development
Table 89. Teva Pharmaceuticals Company Details
Table 90. Teva Pharmaceuticals Business Overview
Table 91. Teva Pharmaceuticals Neurodegenerative Diseases Drug Product
Table 92. Teva Pharmaceuticals Revenue in Neurodegenerative Diseases Drug Business (2016-2021) & (US$ Million)
Table 93. Teva Pharmaceuticals Recent Development
Table 94. Orion Pharma Ltd Company Details
Table 95. Orion Pharma Ltd Business Overview
Table 96. Orion Pharma Ltd Neurodegenerative Diseases Drug Product
Table 97. Orion Pharma Ltd Revenue in Neurodegenerative Diseases Drug Business (2016-2021) & (US$ Million)
Table 98. Orion Pharma Ltd Recent Development
Table 99. UCB S.A Company Details
Table 100. UCB S.A Business Overview
Table 101. UCB S.A Revenue in Neurodegenerative Diseases Drug Business (2016-2021) & (US$ Million)
Table 102. UCB S.A Recent Development
Table 103. ACADIA Pharmaceuticals Inc. Company Details
Table 104. ACADIA Pharmaceuticals Inc. Business Overview
Table 105. ACADIA Pharmaceuticals Inc. Neurodegenerative Diseases Drug Product
Table 106. ACADIA Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Drug Business (2016-2021) & (US$ Million)
Table 107. ACADIA Pharmaceuticals Inc. Recent Development
Table 108. Lundbeck Pharmaceuticals Italy S.p.A. Company Details
Table 109. Lundbeck Pharmaceuticals Italy S.p.A. Business Overview
Table 110. Lundbeck Pharmaceuticals Italy S.p.A. Neurodegenerative Diseases Drug Product
Table 111. Lundbeck Pharmaceuticals Italy S.p.A. Revenue in Neurodegenerative Diseases Drug Business (2016-2021) & (US$ Million)
Table 112. Lundbeck Pharmaceuticals Italy S.p.A. Recent Development
Table 113. Mitsubishi Tanabe Pharma America Company Details
Table 114. Mitsubishi Tanabe Pharma America Business Overview
Table 115. Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Product
Table 116. Mitsubishi Tanabe Pharma America Revenue in Neurodegenerative Diseases Drug Business (2016-2021) & (US$ Million)
Table 117. Mitsubishi Tanabe Pharma America Recent Development
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurodegenerative Diseases Drug Market Share by Type: 2020 VS 2027
Figure 2. Immunomodulator Features
Figure 3. Interferons Features
Figure 4. Decarboxylase Inhibitors Features
Figure 5. Dopamine Agonists Features
Figure 6. Others Features
Figure 7. Global Neurodegenerative Diseases Drug Market Share by Application: 2020 VS 2027
Figure 8. Multiple Sclerosis Case Studies
Figure 9. Parkinson's Disease Case Studies
Figure 10. Alzheimer's Disease Case Studies
Figure 11. Spinal Muscular Atrophy (SMA) Case Studies
Figure 12. Others Case Studies
Figure 13. Neurodegenerative Diseases Drug Report Years Considered
Figure 14. Global Neurodegenerative Diseases Drug Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 15. Global Neurodegenerative Diseases Drug Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 16. Global Neurodegenerative Diseases Drug Market Share by Regions: 2020 VS 2027
Figure 17. Global Neurodegenerative Diseases Drug Market Share by Regions (2022-2027)
Figure 18. Global Neurodegenerative Diseases Drug Market Share by Players in 2020
Figure 19. Global Top Neurodegenerative Diseases Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurodegenerative Diseases Drug as of 2020
Figure 20. The Top 10 and 5 Players Market Share by Neurodegenerative Diseases Drug Revenue in 2020
Figure 21. Global Neurodegenerative Diseases Drug Revenue Market Share by Type (2016-2021)
Figure 22. Global Neurodegenerative Diseases Drug Revenue Market Share by Type (2022-2027)
Figure 23. North America Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. North America Neurodegenerative Diseases Drug Market Share by Type (2016-2027)
Figure 25. North America Neurodegenerative Diseases Drug Market Share by Application (2016-2027)
Figure 26. North America Neurodegenerative Diseases Drug Market Share by Country (2016-2027)
Figure 27. United States Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Canada Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Neurodegenerative Diseases Drug Market Share by Type (2016-2027)
Figure 31. Europe Neurodegenerative Diseases Drug Market Share by Application (2016-2027)
Figure 32. Europe Neurodegenerative Diseases Drug Market Share by Country (2016-2027)
Figure 33. Germany Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. France Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. U.K. Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Italy Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Russia Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Nordic Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Neurodegenerative Diseases Drug Market Share by Type (2016-2027)
Figure 41. Asia-Pacific Neurodegenerative Diseases Drug Market Share by Application (2016-2027)
Figure 42. Asia-Pacific Neurodegenerative Diseases Drug Market Share by Region (2016-2027)
Figure 43. China Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Japan Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. South Korea Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Southeast Asia Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. India Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Australia Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Neurodegenerative Diseases Drug Market Share by Type (2016-2027)
Figure 51. Latin America Neurodegenerative Diseases Drug Market Share by Application (2016-2027)
Figure 52. Latin America Neurodegenerative Diseases Drug Market Share by Country (2016-2027)
Figure 53. Mexico Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Brazil Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Neurodegenerative Diseases Drug Market Share by Type (2016-2027)
Figure 57. Middle East & Africa Neurodegenerative Diseases Drug Market Share by Application (2016-2027)
Figure 58. Middle East & Africa Neurodegenerative Diseases Drug Market Share by Country (2016-2027)
Figure 59. Turkey Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Saudi Arabia Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. UAE Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. Biogen Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2016-2021)
Figure 63. Pfizer Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2016-2021)
Figure 64. Roche Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2016-2021)
Figure 65. Novartis Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2016-2021)
Figure 66. Sanofi Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2016-2021)
Figure 67. Teva Pharmaceuticals Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2016-2021)
Figure 68. Orion Pharma Ltd Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2016-2021)
Figure 69. UCB S.A Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2016-2021)
Figure 70. ACADIA Pharmaceuticals Inc. Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2016-2021)
Figure 71. Lundbeck Pharmaceuticals Italy S.p.A. Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2016-2021)
Figure 72. Mitsubishi Tanabe Pharma America Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2016-2021)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Restless Legs Syndrome Market Growth (Status and Outlook) 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 112

According to our LPI (LP Information) latest study, the global Restless Legs Syndrome market size was valued at US$ million in 2023. With growing demand in downstream market, the Restless Legs Syndrome is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Restless Legs Syndrome market. Restless Legs Syndrome are expected to show stable growth in the future market. However, product di......

Global Autism Spectrum Disorder Market Research Report 2024 (Status and Outlook)

Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 110

Report Overview: Autism spectrum disorder is a biologically based neurodevelopmental disorder characterized by persistent deficits in social communication and social interaction and restricted, repetitive patterns of behavior, interests and activities. Diagnosing autism spectrum disorder (ASD) can be difficult, since there is no medical test, like a blood test, to diagnose the disorders. Doctors look at the child's behavior and development to make a diagnosis. Our report studies the market......

Global Epilepsy Therapeutics Market Research Report 2023

Published: 14-Dec-2023        Price: US 2900 Onwards        Pages: 86

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Epilepsy Therapeutics market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Abbott Laboratories - Cephalon - Novartis - Pfizer - Johnson & Johnson - GlaxoSmithKline - Sanofi - Sunovion Pharmaceuticals......

Global Autism Spectrum Disorder Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 30-Nov-2023        Price: US 3380 Onwards        Pages: 109

Market Overview of Global Autism Spectrum Disorder market: According to our latest research, the global Autism Spectrum Disorder market looks promising in the next 5 years. As of 2022, the global Autism Spectrum Disorder market was estimated at USD 464.19 million, and it's anticipated to reach USD 700.88 million in 2028, with a CAGR of 7.11% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of ......

Global Autism Spectrum Disorder Market Status and Outlook 2023-2028

Published: 24-Nov-2023        Price: US 3160 Onwards        Pages: 109

Autism spectrum disorder (ASD) is a complex developmental condition that involves persistent challenges in social interaction, speech and nonverbal communication, and restricted/repetitive behaviors. The effects of ASD and the severity of symptoms are different in each person. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segmen......

Global Epilepsy Therapeutics Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 16-Nov-2023        Price: US 3380 Onwards        Pages: 112

Market Overview of Global Epilepsy Therapeutics market: According to our latest research, the global Epilepsy Therapeutics market looks promising in the next 5 years. As of 2022, the global Epilepsy Therapeutics market was estimated at USD 11157.84 million, and it's anticipated to reach USD 13510.46 million in 2028, with a CAGR of 3.24% during the forecast years. Epilepsy is a group of neurological disorders characterized by seizures. The onset of a seizure can range from a b......

Global Gabapentin Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 12-Oct-2023        Price: US 3380 Onwards        Pages: 98

Market Overview of Global Gabapentin market: According to our latest research, the global Gabapentin market looks promising in the next 5 years. As of 2022, the global Gabapentin market was estimated at USD 1627.13 million, and it's anticipated to reach USD 1844.92 million in 2028, with a CAGR of 2.12% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Gabapentin market, with a sys......

2023-2031 Report on Global Autism Spectrum Disorder Market by Player, Region, Type, Application and Sales Channel

Published: 09-Oct-2023        Price: US 2500 Onwards        Pages: 89

This report studies the Autism Spectrum Disorder market, covering market size for segment by type (Center-Based, In-Home, etc.), by application (1-14 Years Old, 15-25 Years Old, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Otsuka, Astrazeneca, Pfizer, Eli Lilly, Johnson & Johnson, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical analysis of global market for Aut......

Global Gabapentin Market Insights, Forecast to 2029

Published: 27-Sep-2023        Price: US 4900 Onwards        Pages: 112

Gabapentin is a medication used to treat epilepsy, neuropathic pain, hot flashes, and restless legs syndrome. In epilepsy, it may be used for those with partial seizures. It is recommended as one of a number of first line medications for the treatment of neuropathic pain in diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain. The global Gabapentin market is projected to grow from US$ 1572.1 million in 2023 to US$ 1749.7 million by 2029, at a Compound Annual Growth Ra......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs